Procedure Reviewed By: Narinder Sangha Deputy Chief Pharmacist STANDARD OPERATING PROCEDURE

Similar documents
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE

Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Medicines Optimisation Strategy

lithium record book This record book contains information that will also be held in your patient records.

Formulary and Prescribing Guidelines

Care Homes - Homely Remedies Protocol

Policy for the safe use of oral methotrexate

Essential Shared Care Agreement: Lithium

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011

Lithium Therapy. Record book

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

Guidance on Bulk Prescribing for Care Home Residents

Guidance on Bulk Prescribing for Care Home Patients

Medicine Errors. H.Beadle, L.Baxendale, Clinical Governance Pharmacists. Coventry and Warwickshire Partnership Trust Medicines Management Team

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)

NHS GG&C -Mental Health Services. Lithium Ward Bundle

Controlled Drugs Accountable Officers Network Scotland Executive Group. Gabapentin and Pregabalin - Frequently Asked Questions

Improving medication safety

Care homes - Homely remedies

Mental Health Medicines Management Pilot. Community Pharmacy Lithium Support Service Guidance

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

Care homes - Homely remedies

SHARED CARE GUIDELINE

Contributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.

NPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE

West Suffolk Clinical Commissioning Group (WSCCG) Safety audit for methotrexate prescribing for patients in primary care

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

Homely Remedies Guidance for Care Homes

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016

Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16

Lithium Shared Care Protocol and Information for Oxfordshire GPs

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Ref. Version Supersedes Approved for Date approved Document Owner N/A MMT 17/01/2017 Lois Taylor. Switching to Alogliptin (Vipidia )

Aim. Managing high risk medicines in primary care. Intended outcomes. Introduction. Risk associated with prescribing

Patient Safety Alert NPSA 2009/PSA005 Safer lithium therapy

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Introduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients)

v.1.0 Date: December 2015 Cathy Riley - Director of Pharmacy Policy and Procedures Committee Policy and Procedures Committee

Medication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016

PATIENT SAFETY ALERT

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

:Connected care. Norfolk and Suffolk NHS Foundation Trust

Unit 204 Assist with the assembly of prescribed items

Standard Operating Procedure for Use of Opioid Transdermal Patches in homes within NHS Sutton CCG

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)

The first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit

SAMPLE. This direction was authorised on 4/5/2007. The direction will be reviewed by 4/5/2009

Monitoring of patients prescribed lithium

Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

SHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance

Depression: selective serotonin reuptake inhibitors

Initiation of Clozapine Treatment Community Patients

ESCA: Cinacalcet (Mimpara )

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures

NRT Voucher redemption scheme service specification

New regulatory requirements DPCS Regulations 2017

DENOSUMAB SHARED CARE GUIDLINES

ADMINISTRATION OF INSULIN

Patient Group Directions (PGDs)

A three month project September December 2016

Medicines in Scotland: What s the right treatment for me? Information for patients and the public

HOLY FAMILY CATHOLIC SCHOOL MEDICATION AND ASTHMA POLICY

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

BNSSG Shared Care Guidance Please complete all sections

Lithium continuing care guideline summary (refer to full guidelines for further information)

Procedure for the prescribing and administration of insulin

Developed By Name Signature Date

Brook Green Centre for Learning. Policy and Guidance for Supporting Pupils with Medical Needs

Clinician Responsible for Training and Review: Emergency Department Consultant

Azathioprine treatment for respiratory conditions. Information for patients Respiratory Medicine - Asthma

PROCEDURE: SABP/EXECUTIVE BOARD/0017/PROCEDURE 11. Administration

Safe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland

PATIENT GROUP DIRECTION PROCEDURE

Seasonal Flu Vaccine Offers 2015/16

Drug Prescribing. Ravi Menon

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME

Prescription only medicines (POMs)

ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.

Medicines Management Group

Autologous plasma eye drops. Patient information

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5

Benzodiazepines and Hypnotics

Buprenorphine used in the treatment of opioid dependence: availability and price

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Title Management of Children and Young People with Newly Diagnosed Type 1 Diabetes Mellitus Guideline

1. Intrathecal must never be abbreviated to IT on a prescription form True / False

Diabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust

The prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics

Patient Safety Alert NPSA/2011/PSA003 The adult patient s passport to safer use of insulin

CP80 Version: V01. Acute Oncology Management Service Date approved: 8 th May 2015 Date ratified: 1 st June 2015 Review date: 1 st June 2017

Identifying and reducing medication errors in mental health

PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist

BNSSG Shared Care Guidance Please complete all sections

Transcription:

Written By: Objective By: ed By: To ensure safe and consistent working practice throughout Black Country Partnership Foundation Trust (BCPFT) and to avoid unnecessary harm to patients on lithium therapy based on NPSA safety alert 'safer lithium therapy' December 2009. Scope All pharmacists and pharmacy technicians working within BCPFT. Pharmacy technicians (Band 5 or above with training) may order lithium in the absence of a pharmacist, provided the patient s Clinical Pharmacy Profile has been signed by a pharmacist and the plasma level is checked and within range. The technician must seek further advice if necessary before placing the order. Target range: Adults 0.4-1.0mmol/L Elderly 0.4-0.8mmol/L (Bipolar disorder NICE Guidelines CG 185 September 2014 (Last updated February 2016) states aim to maintain plasma lithium level between 0.6 0.8 mmol/l in people being prescribed lithium for the first time. Consider maintaining plasma lithium levels at 0.8-1.0 mmol/l for a trial period of at least 6 months for people who have had a relapse while taking lithium or are taking lithium and have subthreshold symptoms with functional impairment. Patient admitted on lithium therapy: 1. Pharmacy technician/pharmacist will complete a Clinical Pharmacy Profile. The brand, dose and formulation must be identified. Check the GP list, patient's own supply or speak to the patient to confirm. Endorse the Administration Card and Clinical Pharmacy Profile with the brand. Where liquid is prescribed, ensure that dose is written in millilitres. Confirm if patient has a valid lithium plasma level within the last 3 months or 7 days after latest dose change. Confirmation can be made via the acute hospitals pathology services system or by viewing results in medical notes. 2. Check that the lithium blood plasma level is within the target range for age group. 3. If not already completed by the doctor, the pharmacist or band 5 or above technician must record the lithium blood plasma level on the Administration Card in the pharmacy box, or on the front of the Administration Card. Use a Page 1 of 6

Written By: By: ed By: pre-printed lithium sticker if available. It also needs to be recorded on the reverse of the Clinical Pharmacy Profile and on the Lithium Level Recording Form (see form attached) in front of the ward or Home Treatment pharmacy folder. 4. If no blood result has been taken in the last 3 months, speak to nursing staff or contact the team doctor immediately to arrange a test. Record in the pharmacy box on the front of the Administration Card. Continue to order a supply but follow up request for blood test the following working day, contact team doctor again if request not actioned. If the patient has been non-compliant in the community, it is good practise to ask for a lithium level to be taken 7 days after admission. 7. Check patient has had renal function, thyroid function, calcium levels and weight/bmi checked at least within the last 6 months/before starting lithium. Record on the reverse of the Clinical Pharmacy Profile. 8. Check if patient has brought their own supply of lithium in from home. Accredited Checking Technician/pharmacist must check supply for suitability for use as per SOP For Using Patient s Own Drugs. Non checker technicians must bring supply to the attention of checker technician/pharmacist. Count number available and record on profile. 9. Write on the front of the Administration Card to check if patient has brought their own lithium record book in. If not, a new one will be required. The lithium record book needs to be kept up-to-date. Patient newly prescribed lithium: 1. Pharmacy technician/pharmacist will complete a Clinical Pharmacy Profile. 2. Priadel will be supplied if no brand specified. Endorse Administration Card and Clinical Pharmacy Profile with Priadel brand. 3. Check if patient has had baseline blood tests for thyroid function, renal function and calcium levels (at least in the last month, depending on disease states/other medication prescribed). Confirmation via the intranet link to acute hospital pathology services system or by viewing results in medical notes. Record evidence of baseline blood tests on the reverse of the Clinical Pharmacy Profile. Check patient has weight/bmi recorded. 4. If no baseline blood test taken contact team doctor and request blood test. Page 2 of 6

Written By: By: ed By: State request in the pharmacy box on the front of the Administration Card. DO NOT SUPPLY UNTIL BLOOD TEST RESULTS RECEIVED. 5. Endorse the front of the Administration Card to indicate that the patient will need a lithium therapy information booklet, alert card and record book. Apply a lithium pre-printed sticker if available and complete the blood result when available. Clinical Checking (Pharmacist only): 1. The pharmacist must check that lithium has been correctly prescribed and sign the clinical check box on the Clinical Pharmacy Profile. 2. Identify any possible interactions and/or contra-indications and inform/discuss with prescriber accordingly. 3. Any relevant details should also be recorded on the reverse of the Clinical Pharmacy Profile or in the patient s notes if applicable. Inpatient Supply: 1. Each patient receiving lithium will be provided with their own supply, in appropriate strengths to be stored in the trolley/cupboard. Lithium will not be kept as a stock item on the wards but will be available in the emergency cupboard. Order supply via the Clinical Pharmacy Profile in original packs. The initial supply must be clinically checked by a pharmacist. Three further supplies via clinical profile can be ordered by a pharmacy technician band 5 or above. 2. The pharmacy technician will monitor quantities of lithium available via routine caddy/trolley checking. When supply falls below 14 days of medication, he/she will request the pharmacist/pharmacy technician Band 5 or above to authorise a further supply. Routine Pharmacy Blood Test Monitoring: 1. The pharmacist/pharmacy technician (band 5 or above) must check blood result status to ensure necessary blood tests have been taken 7 days after dose, formulation or brand change, or addition of a medication which interacts with lithium then every 7 days until level stable, then 3 monthly thereafter. Monitor blood test results for all patients receiving lithium via acute hospitals pathology site before each supply request. Record the latest lithium blood plasma level on the Administration Card, on the reverse Page 3 of 6

Written By: By: ed By: of the Clinical Pharmacy Profile and on the ward Lithium Level Recording Form (see below). 2. Refer any blood results which fall outside of target range (even if doses have been altered accordingly) to ward pharmacist for their intervention if necessary. The pharmacist will then contact a team doctor/duty doctor if necessary to discuss. Refer to the Trust Lithium Policy for further information regarding lithium levels. 3. Check that patients stabilised on lithium therapy have had renal function, thyroid function, calcium levels and weight/bmi checked at least within the last 6 months and record on the reverse of the Clinical Pharmacy Profile. Leaves/Discharges: 1. Lithium must be prescribed on leave/discharge prescription by brand. 2. Confirm that all necessary blood tests have been taken and recorded before ordering medication from SLA Provider Pharmacy. Put the last lithium level and date onto the discharge prescription. 2. Labelled supply can be taken from ward if labelled correctly and if a supply greater than duration of leave/discharge has been risk assessed and confirmed by prescriber. This must be documented on the leave/discharge prescription. Endorse prescription 'from ward' or 'trolley/cupboard'. If a smaller quantity is required, order via SLA Provider Pharmacy. 3. Write on the leave/discharge prescription that the patient s up-to-date lithium record book needs to be given to the patient. 4. After discharge, any remaining unused lithium should be removed from the ward as soon as possible. Page 4 of 6

Written By: By: ed By: LITHIUM MONITORING RECORDING FORM Ward Patient s name, NHS number and date of birth Dose and brand of lithium Lithium level (mmol/l) Other blood results: Comments e.g. baseline checks/6 monthly checks Date bloods analysed/ Initials Reference range for lithium 0.4-1.0 mmol/l (0.4-0.8mmol/L in the elderly) Page 5 of 6

Written By: By: ed By: and Amendment History - to be completed by Corporate Governance Version Date Description of Change 1.1 Mar 2018 ed and nothing changed 1.0 Sep 2015 New SOP for BCPFT Page 6 of 6